Table 1.
Patient Characteristics and Comorbidities
| Total, N = 120 | Group 1, n = 92a | Group 2, n = 28b | P Value | |
|---|---|---|---|---|
| Male sex | 99 (82.5) | 77 (83.7) | 22 (78.6) | 0.71 |
| Age, y | 63.2 ± 1.1 | 67.3 ± 9.8 | 62.2 ± 7.6 | 0.62 |
| LVEF, % | 52.8 ± 9 | 53.3 ± 11.1 | 50.2 ± 14.6 | 0.68 |
| LVEF <35% | 11 (9.2) | 5 (5.4) | 6 (21.4) | |
| CHADS2 score | ||||
| Mean | 1.7 | 1.34 | 2.23 | 0.04 |
| 0 | 25 (20.8) | 25 (27.2) | 0 (0) | |
| 1 | 42 (35) | 34 (36.9) | 8 (28.6) | |
| 2 | 28 (23.3) | 18 (19.5) | 10 (35.7) | |
| 3 | 18 (15) | 13 (14.1) | 5 (17.9) | |
| 4 | 6 (5.0) | 1 (1.1) | 5 (17.9) | |
| 5 | 1 (0.8) | 1 (1.1) | 0 (0) | |
| HTN | 76 (63.3) | 54 (58.7) | 22 (78.6) | 0.10 |
| DM | 17 (14.2) | 7 (7.6) | 10 (35.7) | 0.20 |
| COPD | 21 (17.5) | 13 (14.1) | 8 (28.6) | 0.05 |
| Renal failure | 17 (14.2) | 10 (10.9) | 7 (25) | 0.12 |
| Previous stroke | 10 (8.0) | 4 (4.3) | 6 (21.4) | 0.05 |
| Arteriopathy | 11 (9.1) | 8 (8.7) | 3 (10.7) | 0.7 |
| CAD | 20 (16.7) | 14 (15.2) | 6 (21.4) | 0.54 |
| AMI | 14 (11.7) | 8 (8.7) | 6 (21.4) | |
| PCI‐stent | 8 (6.6) | 5 (5.4) | 3 (10.7) | |
| CABG | 7 (5.8) | 4 (4.3) | 3 (10.7) | |
| DCM | 7 (5.8) | 4 (4.3) | 3 (10.7) | 0.21 |
| Medications | ||||
| ACEI/ARB | 61 (50.8) | 44 (47.8) | 17 (60.7) | 0.2 |
| β‐Blocker | 32 (26.7) | 20 (21.7) | 12 (42.8) | 0.08 |
| Statin | 56 (46.6) | 49 (53.2) | 17 (60.7) | 0.44 |
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; AF, atrial fibrillation; AFL, atrial flutter; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CHADS2, congestive HF, HTN, age ≥75 y, DM, prior stroke/TIA/TE; COPD, chronic obstructive pulmonary disease; DCM, dilated cardiomyopathy; DM, diabetes mellitus; HF, heart failure; HTN, hypertension; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; SD, standard deviation; TE, thromboembolism; TIA, transient ischemic attack.
Data are presented as n (%) or mean ± SD.
Group 1: No previously documented AF; anticoagulation stopped after successful AFL ablation.
Group 2: No previously documented AF; anticoagulation continued after successful AFL ablation.